ATP III

(redirected from Adult Treatment Panel III)

ATP III

Adult Treatment Panel III. A brief overview of the National Cholesterol Education Program’s (NCEP) updated clinical guidelines for detecting, evaluating, and treating high cholesterol in adults.
Summary ATP III recommends that all adults above age 20 should get a fasting baseline lipoprotein profile every 5 years.
Rationale The profile is a parameter which, like diabetes, hypertension and other “traditional” heart disease risk factors, serves as a basis for determining the intensity of risk-reducing interventions.
Mentioned in ?
References in periodicals archive ?
Prevalence of metabolic syndrome in urban Pakistan ( arachi): comparison of newly proposed international diabetes federation and modified adult treatment panel iii criteria.
Metabolic syndrome, based on criteria of the modified National Cholesterol Education Program's Adult Treatment Panel III (NCEP-ATP III), was more common among those with acne (17% vs.
Three definitions for the metabolic syndrome were applied, revised National Cholesterol Education Program's Adult Treatment Panel III (NCEP ATP III) criteria, the International Diabetes Federation (IDF) criteria, and the Chinese Diabetes Society (CDS) criteria.
All definitions show the central role of abdominal obesity, despite Adult Treatment Panel III (ATP III) (Expert Panel on Detection, E.
The study's primary outcomes were measured using the Framingham risk algorithm to assess the 10-year risk of having a cardiovascular event and the Adult Treatment Panel III diagnostic criteria to assess for metabolic syndrome.
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
As part of its national lipid treatment guidelines, the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) has included non-HDL as a secondary goal of therapy.
Such patients would not be recommended for statin therapy according to Adult Treatment Panel III guidelines.
For all patients aged 18-21 years, the guidelines recommend measuring one nonfasting non-HDL or FLP, and then reviewing the results with patients and managing them with lipid algorithms per Adult Treatment Panel III as needed.
Methodology: This study was carried out in 83 patients having at least three MetS diagnosis criteria recommended by National Cholesterol Education Program Adult Treatment Panel III.
Measurement of C-reactive protein, another hot topic, is rated class III (no benefit) in asymptomatic adults who are defined as high-risk by the Adult Treatment Panel III standard of a greater than 20% 10-year risk.
Patients in this trial are characterised as having very high triglyceride levels according to the National Cholesterol Education Program Adult Treatment Panel III treatment guidelines.

Full browser ?